Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, comments on the use of measurable residual disease (MRD) to predict depth of response to treatment and patient outcomes, highlighting data from clinical trials evaluating the feasibility of MRD-guided therapy. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
